Health sciences company PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) this morning issued an updated on its soluble gel (“Sol-gel”) drug delivery research and development program, which involves testing an array of cannabis strains for the development and commercialization of cannabinoid-based Sol-gels. Per the update, the program uses five distinct Cannabis sativa L. strains containing an assortment of CBD:THC concentrations, enabling the development of medicinal cannabis products tailored for a broad range of ailments and diseases. The current focus of the Sol-gel program is on preparing formulations containing fixed CBD:THC concentrations that can be utilized with a custom applicator to safely and consistently deliver the compounds to the central nervous system in predefined ratios. As PreveCeutical notes, conventional methods of nasal drug delivery, such as drops and sprays, fail to deliver the therapeutics far enough into the nasal cavity and are rapidly removed by the nose’s self-cleaning mechanisms, decreasing their efficacy. The company’s Sol-gel formulations aim to resolve these issues, making them an ideal vehicle for the nose-to-brain delivery of a host of therapeutic agents.
To view the full press release, visit http://nnw.fm/yG3XB
About PreveCeutical Medical Inc.
PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products. PreveCeutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; the Program; Nature Identical™ peptides for treatment of various ailments; non-addictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury). PreveCeutical sells CELLB9®, an Immune System Booster. CELLB9® is an oral solution containing polarized and potentiated essential minerals extracted from a novel peptide obtained from Caribbean Blue Scorpion venom. This product is available on the company’s website. For more information about PreveCeutical, please visit www.PreveCeutical.com
More from NetworkNewsBreaks
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information, please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
[email protected]